Find Merimepodib manufacturers, exporters & distributors on PharmaCompass

Merimepodib

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

15 Drugs in Development

15 Drugs in Development

DIGITAL CONTENT

5 NEWS #PharmaBuzz

media
5 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

15DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 198821-22-6, Vx-497, Mmpd, Vi-21497, 2zl2ba06fu, (s)-tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate

Molecular Formula

C₂₃H₂₄N₄O₆

Molecular Weight

452.5 g/mol

InChI Key

JBPUGFODGPKTDW-SFHVURJKSA-N

FDA UNII

2ZL2BA06FU

Merimepodib is an inosine monophosphate dehydrogenase (IMPDH) inhibitor with activity against hepatitis C virus (HCV). IMPDH catalyzes the rate-limiting step in the de novo synthesis of guanine nucleotides, and treatment with merimepodib reduces the intracellular guanine nucleotide levels that are required for RNA and DNA synthesis, resulting in antiproliferative and antiviral effect.

1 2D Structure

Merimepodib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate

2.1.2 InChI

InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1

2.1.3 InChI Key

JBPUGFODGPKTDW-SFHVURJKSA-N

2.1.4 Canonical SMILES

COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)OC3CCOC3)C4=CN=CO4

2.1.5 Isomeric SMILES

COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)O[C@H]3CCOC3)C4=CN=CO4

2.2 Other Identifiers

2.2.1 UNII

2ZL2BA06FU

2.3 Synonyms

2.3.1 MeSH Synonyms

1. N-3-(3-(3-methoxy-4-oxazol-5-ylphenyl)ureido)benzylcarbamic Acid Tetrahydrofuran-3-yl Ester

2. Vx 497

3. Vx-497

2.3.2 Depositor-Supplied Synonyms

1. 198821-22-6

2. Vx-497

3. Mmpd

4. Vi-21497

5. 2zl2ba06fu

6. (s)-tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate

7. Vi-21,497

8. Chembl304087

9. [(3s)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate

10. Vx497

11. Merimepodib, Vi-21497, Vx-497

12. (s)-tetrahydro-3-furyl (m-(3-(3-methoxy-4-(5-oxazolyl)phenyl)ureido)benzyl)carbamate

13. Carbamic Acid, ((3-((((3-methoxy-4-(5-oxazolyl)phenyl)amino)carbonyl)amino)phenyl)methyl)-, (3s)-tetrahydro-3-furanyl Ester

14. Vx 497

15. Merimepodib [usan:inn]

16. Unii-2zl2ba06fu

17. Merimebodib

18. Carbamic Acid, [[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-, (3s)-tetrahydro-3-furanyl Ester

19. Merimepodib [usan]

20. Merimepodib [mi]

21. Merimepodib [inn]

22. Merimepodib (usan/inn)

23. Merimepodib [who-dd]

24. Schembl329922

25. Gtpl10741

26. Dtxsid70173639

27. [[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]carbamic Acid (3s)-tetrahydro-3-furanyl Ester

28. Bcp28336

29. Ex-a1201

30. Yha82122

31. Zinc3975663

32. Bdbm50102249

33. Fd5020

34. Mfcd09837807

35. S6689

36. Db04862

37. N-3-(3-(3-methoxy-4-oxazol-5-ylphenyl)ureido)benzylcarbamic Acid Tetrahydrofuran-3-yl Ester

38. Ncgc00378589-01

39. Ac-35396

40. As-75124

41. Hy-13986

42. D04936

43. A919457

44. Q1727082

45. (3s)-oxolan-3-yl N-{[3-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)phenyl]methyl}carbamate

46. [(3s)-tetrahydrofuran-3-yl] N-[[3-[(3-methoxy-4-oxazol-5-yl-phenyl)carbamoylamino]phenyl]methyl]carbamate

47. {3-[3-(3-methoxy-4-oxazol-5-yl-phenyl)-ureido]-benzyl}-carbamic Acid (s)-(tetrahydro-furan-3-yl) Ester

48. {3-[3-(3-methoxy-4-oxazol-5-yl-phenyl)-ureido]-benzyl}-carbamic Acid Tetrahydro-furan-3-yl Ester

49. Carbamic Acid, N-[[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-, (3s)-tetrahydro-3-furanyl Ester

50. N-[3-3-[3-methoxy-4-(5-oxazolyl)phenyl]ureido]benzyl]carbamic Acid Tetrahydrofuran-3-(s)-yl Ester

2.4 Create Date

2005-08-01

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₂₄N₄O₆
Molecular Weight	452.5 g/mol
XLogP3	2.1
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	8
Exact Mass	452.16958450 g/mol
Monoisotopic Mass	452.16958450 g/mol
Topological Polar Surface Area	124 Å²
Heavy Atom Count	33
Formal Charge	0
Complexity	652
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

For the treatment of hepatitis C virus (HCV) infection.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Merimepodib, an oral drug, contains a novel inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme responsible for stimulating the production of lymphocytes. Merimepodib has the potential to exert direct antiviral activity, as well as affect the immune response by acting on lymphocyte migration and proliferation. Consequently, merimepodib may be an effective treatment for hepatitis C virus (HCV) infection, as the disease involves both viral proliferation and liver inflammation.

5.2 Mechanism of Action

Merimepodib is a orally active inhibitor of inosine monophospate dehydrogenase (IMPDH). IMPDH inhibition leads to a reduction in intracellular guanosine triphosphate (GTP), a molecule required for DNA and RNA synthesis.

Drugs in Development